Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria
Martin Inzinger, Katharina Wippel-Slupetzky, Wolfgang Weger, Leo Richter, Alexander Mlynek, Barbara Fleischander, Christine Scheurecker, Nikolaus Sandor, Daniela Mairhofer, Paul G. Sator, Sabine Moser-Oberthaler, Nina Häring, Petra Viznerova, Clemens Painsi, Adrian Tanew, Peter Ponholzer, Rafaella Tatarski, Wilhelm Brenner, Georg Stingl, Wolfgang Salmhofer, Klemens Rappersberger, Georg Klein, Werner Saxinger, Josef Auböck, Claudia Kölli, Franz Trautinger, Andreas Steiner, Gudrun Ratzinger, Robert Strohal, Elisabeth Riedl, Bernhard Lange-Asschenfeldt, Hubert Pehamberger, Beatrix Volc-Platzer, Sylvia Selhofer, Franz Josef Legat, Robert Müllegger, Norbert Reider, Matthias Schmuth, Helmut Hintner, Angelika Hofer, Alexandra Gruber-Wackernagel, Werner Aberer, Franz Quehenberger, Peter Wolf
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.